

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
Laminar Direct Capital, L.L.C. as successor in interest to Laminar Direct Capital, L.P.	04/24/2012
RECEIVING PARTY DATA	
Name:	TRIAX Pharmaceuticals, LLC
Street Address:	20 Commerce Dr.
City:	Cranford
State/Country:	NEW JERSEY
Postal Code:	07016
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	11418514
Application Number:	11459778
Patent Number:	7981877
Patent Number:	7378405
CORRESPONDENCE DATA	
Fax Number:	(215)851-8383
Email:	cstrom@eckertseamans.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Christopher J. Strom
Address Line 1:	50 South 16th Street, 22nd Floor
Address Line 4:	Philadelphia, PENNSYLVANIA 19102
ATTORNEY DOCKET NUMBER:	294857-2
NAME OF SUBMITTER:	Christopher J. Strom
Total Attachments: 4 source=cover#page1.tif source=release#page1.tif source=release#page2.tif source=release#page3.tif	

OP \$160.00 11418514

## RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies)**

Laminar Direct Capital, L.L.C. as successor in interest to Laminar Direct Capital, L.P.

Additional name(s) of conveying party(ies) attached?  Yes  No

**2. Name and address of receiving party(ies)**

Name: TRIAX PHARMACEUTICALS, LLC

Internal Address: \_\_\_\_\_

Street Address: 20 Commerce Dr.

City: Cranford,

State: NJ

Country: US

Zip: 07016

Additional name(s) & address(es) attached?  Yes  No

**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) April 25, 2012

- Assignment  Merger  
 Security Agreement  Change of Name  
 Joint Research Agreement  
 Government Interest Assignment  
 Executive Order 9424, Confirmatory License  
 Other Release of Security Interest

**4. Application or patent number(s):**

This document is being filed together with a new application.

A. Patent Application No.(s)

11/418,514 and 11/459,778

B. Patent No.(s)

7,378,405 and 7,981,877

Additional numbers attached?  Yes  No

**5. Name and address to whom correspondence concerning document should be mailed:**

Name: Christopher J. Strom

Internal Address: Eckert Seamans Cherin & Mellott, LLC

Street Address: 50 South 16th Street, 22nd Floor

City: Philadelphia

State: PA Zip: 19102

Phone Number: 215-851-8400

Fax Number: 215-851-8383

Email Address: cstrom@eckertseamans.com

**6. Total number of applications and patents involved:** 4

**7. Total fee (37 CFR 1.21(h) & 3.41)** \$ 160.00

- Authorized to be charged to deposit account  
 Enclosed  
 None required (government interest not affecting title)

**8. Payment Information**

Deposit Account Number \_\_\_\_\_

Authorized User Name David J. Federline

**9. Signature:**

/Christopher J. Strom/

Signature

April 26, 2012

Date

Christopher J. Strom

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

**TERMINATION AND RELEASE OF SECURITY INTEREST  
IN PATENTS**

This **TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS**, dated as of April 25, 2012 ("Release"), is made by Laminar Direct Capital, L.L.C., as successor in interest to Laminar Direct Capital, L.P., as Collateral Agent (the "Collateral Agent") in favor of Triax Pharmaceuticals, LLC (the "Grantor").

**WHEREAS**, pursuant to that certain Security and Pledge Agreement dated as of August 31, 2007 as amended, restated, supplemented, modified, extended, renewed or replaced from time to time, the "Security Agreement") by and among the Obligors party thereto and the Collateral Agent, each Obligor granted to the Collateral Agent, for the ratable benefit of the Lenders, a continuing security interest in, and a right to set off against, any and all right, title and interest of such Obligor in, to, and under all the General Intangibles (including all contract rights and all patents, trademarks (including the goodwill associated therewith) and copyrights and applications for any of the foregoing) and Proceeds of the foregoing;

**WHEREAS**, pursuant to the Security Agreement, Grantor, an Obligor, executed and delivered to Collateral Agent, for the ratable benefit of the Lenders, the Notice of Grant of Security Interest in Patents dated as of August 31, 2007 ("Notice"); and

**WHEREAS**, the Notice was recorded at the United States Patent and Trademark Office ("USPTO") on September 25, 2007 at Reel 019870 Frame 0970.

**NOW THEREFORE**, in consideration of the mutual promises and undertakings set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intention of being legally bound hereby, Collateral Agent, on behalf of the Lenders, and Grantor (the "parties") agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or Notice.

**SECTION 2. Termination and Release.** Collateral Agent, on behalf of the Lenders, without representation, warranty, or recourse, hereby:

(a) terminates, cancels, discharges, and releases the mortgage, pledge, and hypothecation and lien on and security interest in and to the right, title, and interest in, to, and under all the Obligor's General Intangibles (including all contract rights and all patents, trademarks (including the goodwill associated therewith) and copyrights and applications for any of the foregoing) and Proceeds of the foregoing, including the foregoing listed on Schedule A attached hereto; and

(b) authorizes the recordation of this Release with the USPTO.

IN WITNESS WHEREOF, the Collateral Agent, on behalf of the Lenders, has caused this Termination and Release of Security Interest in Patents to be duly executed as of the date first set forth above.

Collateral Agent:

Laminar Direct Capital, L.L.C.,  
as successor in interest to Laminar Direct Capital, L.P.  
as Collateral Agent

By: Robert T. Ladd  
Name: Robert T. Ladd  
Title: Authorized Signatory

Termination and Release of Security Interest in Patents

PATENT  
REEL: 028114 FRAME: 0340

Schedule A

Triax Pharmaceuticals, LLC  
(Delaware LLC)

U.S. Patents

Issued Patents

Description	Patent No.	Issued
STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	7981877	07/19/11
STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION	7378405	05/27/08

Pending Applications

Description	Appl. No.	Filing Date
SKIN TREATMENT EDUCATIONAL KIT	11418514	05/04/06
7-DIMETHYLAMINO-6-DEMETHYL-6-DEOXYTETRACYCLINE SKIN TREATMENT KIT	11459778	07/25/06